Xcelerate Inc. · OTC:XCRT
Xcelerate — Investor Presentation (April 2023)
21 slides from Xcelerate's investor presentation, April 2023
Slide 1: Xcelerate, Inc. OTCQB: XCRT
CV) XCELERATE, INC. S28L ) OTCQB: XCRT
Slide 2: About Xcelerate
ABOUT XCELERATE Xcelerate seeks to acquire rather than develop its technology / healthcare delivery. We understand that engineering advancements in non-medical fields often have unrealized applications in medical technology & clinical care and the silos existing between advanced engineering and medi
Slide 3: About Xcelerate (continued)
ABOUT XCELERATE (CONTINUED) Xcelerate has assembled an internationally recognized team Xcelerate is unique in that it was designed from inception of translational clinicians and engineers to identify and to span the divide between initial non-medical 01 acquire engineering advancements and intellect
Slide 4: Board Of Directors
Board Of Directors Michael O’Shea (C.E.O. Chairman) Mike O’Shea is a forensic accountant and licensed financial investigator. He has worked closely with such agencies as the Federal Deposit Insurance Corporation, Resolution Trust Corporation, FBI, Office of the Controller of the Currency, US Secret
Slide 5: Board Of Directors (continued)
Board Of Directors (continued) Jason Householder (Director) Jason Householder, Co-Founder and CEO of Charlotte based LenDRgroup Consulting, has more than a decade of experience in the healthcare banking field and specializes in assisting medical, dental, and veterinary practices to devise strategies
Slide 6: Advisory Board
ADVISORY BOARD Dr. Anja Glisovic, Acting Chief Science Officer Dr. Glisovic received her PhD in X-Ray and Material Physics from Germany’s Georg-August Universitat in 2007. She went on to become the head of the R&D Laboratory, Chief Science Officer, and R&D Project Leader for the Fraunhoffer Institut
Slide 7: Advisory Board (continued)
ADVISORY BOARD (continued) Dr. Barry Marshall, AC. FRACP, FAA,FRS,MBBS-UWA Professor Barry Marshall is a Nobel Prize Laureate, Professor of Clinical Microbiology at The University of Western Australia. Professor Marshall was awarded the 2005 Nobel Prize for Physiology or Medicine for their discovery
Slide 8: Advisory Board (continued)
ADVISORY BOARD (continued) Fabian Urquijo Fabian is originally from Argentina. He joined the Procter & Gamble Company, as an Assistant Brand Manager in 1997. At P&G, he enjoyed an 18-year career, within the Marketing and General Management functions. He served in various roles of increasing responsi
Slide 9: Afyasasa Africa
Afyasasa Africa In early 2022, Xcelerate acquired a controlling interest in AfyaSasa Africa, LLC, (“ASA”) a start-up medical technology and virtual health company, founded by Dr. Dilan Ellegala and Doyle Word. This technology is centered around patented and patent pending software that uses and inco
Slide 10: Afyasasa Africa
Afyasasa Africa In March 2023 Xcelerate announced that Afya Sasa Africa LLC, a subsidiary of Xcelerate, signed an Agreement to implement its Artificial Intelligence (AI) based health services at The National Hospital of Tanzania, Muhimbili National Hospital, Mloganzila in Dar es Salaam, Tanzania, th
Slide 11: A Generational Shift
Bridging the gap in healthcare with Artificial Intelligence based health services: A Generational Shift Powered by AdviNow Patented Automated Artificial Intelligence
Slide 12: Solution: Artificial intelligence based health services
Solution Artificial intelligence based health services Digital From Door, Smart Al and Augmented Reality (AR) Scribe—Differential Optimized Comprehensive Check-In Triage Driven Patient Measurements EMR Integration Doctor Consult Follow Up • Appropriare Care Path • BP, temp, weight, • Al charts patie
Slide 13: 1 Billion People: Executed Agreements
Executed Agreements EXCLUSIVE RIGHTS FOR 10 INITIAL PRORITY MARKETS ACROSS AFRICA A MARKET OVER 1 BILLION PEOPLE
Slide 14: Afya Sasa Tanzania Leadership Team
Afya Sasa Tanzania Leadership Team DILAN ELLEGALA, Managing Director: Head of Technology and Systems MD, FAANS (TZ) Sriyanjit Perera. B.Eng. MBA (TZ) (TZ): Mr. Paul Bwathondi CO-FOUNDER, NEUROSURGEON, Health Information Systems Expert, Information System Expert with experience in GLOBAL HEALTH EXPER
Slide 15: Afya Sasa Tanzania Leadership Team
Afya Sasa Tanzania Leadership Team Medical Al Lead (USA): Emanuel Nuwass. MD,MBA,(TZ) Mr. Doyle (D) Bradford Dr. Tom Forsberg Medical Review and HLH Lead Word (USA) Innovative physician leader with an Former Managing Medical Director and An extensive career in International Business impressive clini
Slide 16: MedTech Developments / Patents
MedTech Developments / Patents In 2020 Xcelerate obtained a license for world-wide rights to Patent, #10,718,586, as it pertains to design, manufacture, and world-wide distribution of medical devices. This License also encompasses a newly filed Patent Application, #17/017,546, that further enhances
Slide 17: Medtech Developments Patents
With Xcelerate's InTool-series of surgical instruments and devices we bring a new “first-person view” to the surgical theatre. By integrating cameras directly into surgical tools, we allow the surgeon to follow and perform the procedure from his tool’s perspective. This new viewpoint has the potenti
Slide 18: Patent Portfolio
The portfolio consists of four issued and one pending U.S. patents, two issued Patent Portfolio and one pending European patent, as well as certain licensing agreements in In May of 2022 Xcelerate acquired a portfolio of conjunction with research developed by patents, patents pending and technology
Slide 19: Patent Portfolio
Patent Portfolio U.S. Patents European Patents – Validated U.S. 9,889,151: methods of treating specific cancers with a composition releasing orthosilicic acid in vivo In Germany, Spain, France, The U.S. 9,333,224: methods of treating bacterial infection United Kingdom, Ireland, Italy with a composit
Slide 20: Consumer Health / Skin Care Products
Consumer Health / Skin Care Products In August 2022 the Company established the Xcelerate Brands division to pursue the development and marketing of certain of these patented technologies as over-the-counter healthcare products. Xcelerate established a new Advisory Board to identify marketing/manufa
Slide 21: Corporate Information
Corporate Information Xcelerate, Inc. CORPORATE STRUCTURE: • Symbol: OTCQB – XCRT 110 Renaissance Circle Mauldin, SC 29662 • Cusip: 98401T105 • U.S. Reporting: SEC Reporting - Reg A • Shell: No • Shares Authorized: 1,000,000,000 on 03/15/23 854-900-2020 • Shares Outstanding: 381,446,072 on 03/15/23